Osborne Clarke in Amsterdam has advised lead investors Ysios Capital and Forbion Growth on Northsea Therapeutics' USD 80 million Series C financing round.
The financing round was co-led by Ysios Capital and Forbion Growth and joined by new investors; a large managed care organization, and Hercules Capital, Inc. (NYSE: HTGC). Existing investors Forbion Ventures, venBio, Novo Seeds, Sofinnova, BGV and New Science Ventures all participated.
The proceeds of the fundraising will be used to advance development of NST’s pipeline of Structural Engineered Fatty Acids (SEFA) clinical-stage programs in NASH and other metabolic disorders.
The Osborne Clarke team in Amsterdam consisted of Partner Herke van Hulst and Associate Director Marie-Louise Weeda.
Osborne Clarke’s international life science and healthcare sector team has a strong track record of providing highly sophisticated advice to investors and biotech clients on cutting-edge issues, across multiple service lines. They work with blue chip venture capital firms, the biggest pharma and medical devices companies in the market. Recent notable work from the team in Amsterdam includes advising management in respect of the sale of Viroclinics-DDL to Cerba Healthcare, the investors in respect of the USD 32 million Series B round of VarmX and Lava on the USD 83 mio Series C round of Lava Therapeutics, assisting the shareholders on the sale of MILabs to Rigaku, the sale of Isobionics to BASF and the sale of Breath Therapeutics to Zambon.
Corporate communications and press contacts
Connect with one of our experts
